ES2077670T3 - Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina. - Google Patents

Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina.

Info

Publication number
ES2077670T3
ES2077670T3 ES90901345T ES90901345T ES2077670T3 ES 2077670 T3 ES2077670 T3 ES 2077670T3 ES 90901345 T ES90901345 T ES 90901345T ES 90901345 T ES90901345 T ES 90901345T ES 2077670 T3 ES2077670 T3 ES 2077670T3
Authority
ES
Spain
Prior art keywords
dependent diabetes
idd
early detection
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90901345T
Other languages
English (en)
Inventor
Mark A Atkinson
Noel K Maclaren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2077670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Florida filed Critical University of Florida
Application granted granted Critical
Publication of ES2077670T3 publication Critical patent/ES2077670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN NUEVO PROCESO PARA LA DETECCION TEMPRANA DE DIABETES INSULINODEPENDIENTE (IDD). EL NUEVO PROCESO AQUI DESCRITO PERMITE LA DETECCION DESDE EL PRINCIPIO DE LA IDD ANTES DE QUE APAREZCAN LOS SINTOMAS CLINICOS. EL NUEVO PROCESO CONSISTE EN LA DETECCION, EN UNA MUESTRA DE FLUIDO BIOLOGICO, DE UN AUTOANTICUERPO MUY ESPECIFICO DE INDIVIDUOS QUE LUEGO DESARROLLARAN LAS MANIFESTACIONES CLINICAS DE IDD. TAMBIEN SE DESCRIBEN NUEVOS TRATAMIENTOS PARA LA IDD.
ES90901345T 1988-12-13 1989-12-08 Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina. Expired - Lifetime ES2077670T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28363388A 1988-12-13 1988-12-13
US42705189A 1989-10-25 1989-10-25

Publications (1)

Publication Number Publication Date
ES2077670T3 true ES2077670T3 (es) 1995-12-01

Family

ID=26962160

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90901345T Expired - Lifetime ES2077670T3 (es) 1988-12-13 1989-12-08 Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina.

Country Status (8)

Country Link
EP (1) EP0448635B1 (es)
KR (1) KR910700459A (es)
AU (1) AU4815890A (es)
CA (1) CA2005300C (es)
DE (1) DE68924354T2 (es)
DK (1) DK112391A (es)
ES (1) ES2077670T3 (es)
WO (1) WO1990007117A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
JP2649103B2 (ja) * 1990-08-17 1997-09-03 ユニバーシティー オブ フロリダ インシュリン依存性真性糖尿病の早期検出及び処置のための方法及び組成物
WO1992004632A1 (en) 1990-09-07 1992-03-19 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
WO1992006105A1 (en) * 1990-10-02 1992-04-16 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス，インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現
US5407802A (en) * 1991-12-26 1995-04-18 Immulogic Pharmaceutical Corporation Method of accessing the risks of developing type I diabetes
WO1993016725A1 (en) * 1992-02-27 1993-09-02 The Board Of Trustees Of The Leland Stanford Junior University Early antigen for autoimmune diabetes
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
IL112094A0 (en) * 1994-12-21 1995-03-15 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633251B2 (en) * 1988-02-03 1993-01-28 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Also Published As

Publication number Publication date
KR910700459A (ko) 1991-03-15
AU4815890A (en) 1990-07-10
DE68924354D1 (de) 1995-10-26
EP0448635B1 (en) 1995-09-20
CA2005300C (en) 2000-02-15
CA2005300A1 (en) 1990-06-13
EP0448635A1 (en) 1991-10-02
DK112391D0 (da) 1991-06-12
WO1990007117A1 (en) 1990-06-28
DE68924354T2 (de) 1996-02-22
DK112391A (da) 1991-06-12

Similar Documents

Publication Publication Date Title
ES2077670T3 (es) Metodos y composiciones que sirven para la deteccion precoz y el tratamiento de la diabetes mellitus dependiente de la insulina.
Tanner The role of environmental toxins in the etiology of Parkinson's disease
ES2093714T3 (es) Metodos y composiciones para la deteccion y el tratamiento precoces de la diabetes mellitus insulinodependiente.
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
EP1474510A4 (en) COMPOSITIONS AND METHODS FOR DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNITIES
ES2121915T3 (es) Ligandos del receptor eck.
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
AR005075A1 (es) Uso de un compuesto azaheterociclico n-subustituido, uso de una composicion farmaceutica util para la preparacion de un medicamento para reducir el nivel de glucosa en sangre y/o inhibir la actividad del cgrp y composicion farmaceutica que los contiene
PT665886E (pt) Rearranjo de complexos de ciclina e suas utilizacoes
Lewis et al. The assay of warfarin in plasma or stool
NO914217D0 (no) Sakkarinderivater nyttige som proteolytiske enzyminhibitorer og fremstilling derav
FR2590673A1 (fr) Dispositif de test autonome miniaturise a usage unique
DK228789D0 (da) Fremgangsmaade til fremstilling af et emne af harpiks ved fotopolymerisation og anvendelse af denne fremgangsmaade
ES2103582T3 (es) Ensayo y kit.
ES8308928A1 (es) Metodo de detectar la presencia de adn de neisseria gonorrhoeae en material de muestra de pacientes.
Pijoan et al. Determination of blood ascorbic acid
BR0001794A (pt) Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
BR0316666A (pt) Novo uso de sulfato de dextrano
Amaliya et al. Java project on periodontal diseases: effect of vitamin C/calcium threonate/citrus flavonoids supplementation on periodontal pathogens, CRP and H b A 1c
ATE43254T1 (de) Verfahren zur hemmung der reduktion des glucose- gehalts im blut.
FI99114B (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
Lee et al. Inhibition of advanced glycation end product formation by burdock root extract
BR9608147A (pt) Método para descontaminação microbiana de plaquetas sanguìneas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 448635

Country of ref document: ES